TransMedics Group, Inc. (TMDX)
$
94.31
-4.74 (-5.03%)
Key metrics
Financial statements
Free cash flow per share
3.9038
Market cap
3.4 Billion
Price to sales ratio
5.6114
Debt to equity
0.9928
Current ratio
7.1416
Income quality
1.0134
Average inventory
46.7 Million
ROE
0.5388
Technology
Technology – consumer electronics
Largecap
With a market cap of 121,78 bil stock is ranked 1
Low risk
ISS score of this stock is ranked 1
Company description
Profile
TransMedics Group, Inc. is a commercial-stage medical technology company focused on revolutionizing organ transplant therapy for patients with end-stage organ failure, both in the United States and globally. The company has developed the Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that employs proprietary technology to provide near-physiologic conditions for donor organs outside the human body. Among its offerings, OCS LUNG preserves standard criteria donor lungs for double-lung transplantation, OCS Heart enables the extracorporeal perfusion and preservation of donor hearts, and OCS Liver is dedicated to the preservation of donor livers. The company reported an income before tax of $107,522,000.00 showcasing its pre-tax profitability, while the total costs and expenses for the company are $496,911,000.00 reflecting its overall spending. The net income ratio is $0.31 reflecting the company's profitability margin, and the operating income ratio is $0.18 indicating the company's operational profitability margin. Furthermore, the net total of other income and expenses is -$1,061,000.00 reflecting non-core financial activities. In terms of investment potential, the stock is reasonably priced at $122.29 appealing to a broad range of investors. It also boasts a high average trading volume of 815,727.00 indicating strong liquidity in the market. With a mid-range market capitalization of $3,235,064,154.00 TransMedics is recognized as a steady performer among its peers. The company operates as a key player in the Medical - Devices industry, contributing significantly to the overall market landscape. Furthermore, it belongs to the Healthcare sector, driving innovation and growth, thereby positioning itself as a vital entity in the advancement of medical technology for organ transplantation.
Is TransMedics Group, Inc. (TMDX) a good investment?
Investing in TransMedics Group, Inc. (TMDX) depends on multiple factors, including revenue growth, profit margins, debt-to-equity ratio, earnings per share, and return on equity. Analysts have rated it as B-, with a Bearish outlook. Always conduct your own research before investing.
What is TransMedics Group, Inc. (TMDX)'s stock forecast?
Analysts predict TransMedics Group, Inc. stock to fluctuate between $62.23 (low) and $156 (high) in the next 365 days, reflecting market expectations and potential volatility.
What is TransMedics Group, Inc.'s market capitalization?
As of 2026-03-30, TransMedics Group, Inc.'s market cap is $3,235,064,154, based on 34,302,451 outstanding shares.
How does TransMedics Group, Inc. compare to competitors like Meta Platforms, Inc. Class A Common Stock?
Compared to Meta Platforms, Inc. Class A Common Stock, TransMedics Group, Inc. has a Lower Market-Cap, indicating a difference in performance.
How can I buy TransMedics Group, Inc. (TMDX) stock?
To buy TransMedics Group, Inc. (TMDX) stock: Open a brokerage account (e.g., Robinhood, TD Ameritrade, E-Trade). Search for TMDX. Place an order (Market, Limit, etc.).
What is the best time to invest in TransMedics Group, Inc.?
The best time to invest depends on market trends and technical indicators, which show a Bearish trend based on economic conditions and company performance.
How did TransMedics Group, Inc. perform in the last earnings report?
Revenue: $605,494,000 | EPS: $5.60 | Growth: 423.36%.
Where can I find TransMedics Group, Inc.'s investor relations reports?
Visit https://www.transmedics.com/investor-relations for detailed financial reports.
Where can I find historical stock prices for TransMedics Group, Inc.?
You can explore historical data from here
What is the all-time high and low for TransMedics Group, Inc. stock?
All-time high: $177.37 (2024-08-23) | All-time low: $10 (2022-02-24).
What are the key trends affecting TransMedics Group, Inc. stock?
Key trends include market demand, economic conditions, interest rates, and industry competition, which influence the stock's performance.
News
zacks.com
TransMedics (TMDX) reported earnings 30 days ago. What's next for the stock?
zacks.com
TMDX rides OCS adoption and strong fourth-quarter results, but margin pressure raises questions for investors.
seekingalpha.com
TransMedics is positioned for accelerating growth, with revenue expected to expand around 25% in 2026 and free cash flow breakeven by late 2026 or early 2027. TMDX is over the crest of its capex cycle, with investment pressures expected to ease, supporting margin expansion toward a 30% target by 2028. Despite a weak balance sheet and potential for 15% shareholder dilution in 2026, I remain bullish as long as revenue growth stays above 20% y/y.
fool.com
TransMedics remains the top dog in its industry and may have a widening moat. The founder-led company's shares have risen eightfold since 2019.
investors.com
Medical stock TransMedics is in a cup-with-handle base with a buy point of 151.85.
fool.com
TransMedics is helping improve organ transplantation thanks to its innovative organ storage system. The company has posted strong financial results over the past few years, and the stock is soaring.
prnewswire.com
ANDOVER, Mass., Feb. 27, 2026 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today issued additional information on the impact of the valuation allowance on deferred tax assets reported in the Company's fourth quarter financial results for the year ended December 31, 2025.
zacks.com
TransMedics posts 200% EPS surge and 32% revenue growth in Q4, tops estimates and guides for up to 25% sales growth in 2026.
seekingalpha.com
TransMedics Group, Inc. (TMDX) Q4 2025 Earnings Call Transcript
zacks.com
While the top- and bottom-line numbers for TransMedics (TMDX) give a sense of how the business performed in the quarter ended December 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
See all news
